DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the IOL CHEM AND PHARMA LTD (IOLCP) share price today?

IOL CHEM AND PHARMA LTD (IOLCP) is trading at ₹148.33 on the NSE, down 9.59% on the day. Source: DocStoX.

What is the PE ratio of IOL CHEM AND PHARMA LTD?

IOL CHEM AND PHARMA LTD has a price-to-earnings (PE) ratio of 43.1 in the Healthcare sector.

What is the market capitalisation of IOL CHEM AND PHARMA LTD?

IOL CHEM AND PHARMA LTD has a market capitalisation of approximately ₹4,365 crore.

IOL CHEM AND PHARMA LTD

IOLCP·NSE·Healthcare

₹148.33▼ -15.74 (-9.59%)

Healthcare · Pharmaceuticals

Revenue under pressure recently

Day₹146.63

₹164.70

52W₹67

₹18072%

Open

₹164.70

High

₹164.70

Low

₹146.63

Prev Close

₹164.07

Volume

62.88L

VWAP

₹152.59

Snapshot

Key fundamentals

Market Cap

₹4,365 Cr

P/E Ratio

43.12Expensive

P/B Ratio

2.74

EPS

₹3.44

Book Value

₹61.27

ROE

5.99%Weak

ROCE

9.00%Weak

Dividend Yield

0.59%

Debt / Equity

0.08Low

Face Value

₹2.00

52W High

₹179.60

52W Low

₹67.19

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatMedium uncertainty

Fair value estimate

₹60

▼ 59.8%downside

Trading at ₹148 — 60% above our estimate

BearFair valueBull

₹51₹60₹69

/100

Business quality — Watch the fundamentals

Growth 0Profitability 10Efficiency 3Valuation 57

Plain English

Our view

Revenue under pressure recently
Virtually debt-free balance sheet
Weak returns on equity (6%)

Strengths

Virtually debt-free balance sheet
Promoters hold a controlling stake

Risks

Weak returns on equity (6%)
Revenue has been shrinking
Fundamental red flags (Piotroski 3/9)

How we got there

Fair value methods

Residual income

6% ROE fading to 12% over ~3 yrs, on ₹61 book

₹57

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹69

Analyst target

No analyst coverage

—

Blended fair value₹60

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Promoters hold a controlling stake

Bear case

Weak returns on equity (6%)
Revenue has been shrinking
Fundamental red flags (Piotroski 3/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

43.1Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

6.0%Weak

Above 15% is considered healthy for Indian equities

ROCE

9.0%Weak

Above 18% means capital is working hard

Debt/Eq

0.08Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹4,365 Cr

P/B

2.74

EPS

₹3.44

Div Yield

0.59%

What changed

Recent changes

Foreign investors+3.2% stake last quarter
Domestic institutions+0.4% stake last quarter
Promoters+4.80% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 43.1×

Growth

Slow

+2% rev CAGR

Profitability

Modest

6.0% ROE

Financial health

Rock solid

D/E 0.08

Momentum

N/A

No technicals

Today

Trading activity

Delivery %39.0%

Turnover₹9595.47L Cr

Trades42,247

VWAP₹152.59

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+1.5%

+3.4%

10Y

+14.9%

Profit

-0.6%

-20.9%

10Y

—

EPS

—

10Y

—

Profile

Pros

Company is almost debt free.
Company has been maintaining a healthy dividend payout of 22.1%
Promoter holding has increased by 4.80% over last quarter.

Watch-outs

Cons

Stock is trading at 2.79 times its book value
The company has delivered a poor sales growth of 3.35% over past five years.
Company has a low return on equity of 7.73% over last 3 years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Promoters raised their stake by 4.80 pts; foreign investors bought 3.15 pts; domestic institutions added 0.41 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

62%

Promoter

Promoters

62.3%+4.80

Public

32.4%-8.37

FII / FPI

4.9%+3.15

DII

0.4%+0.41

Total shareholders

1,19,311-12,239 QoQ

Quarterly trend

Ownership over time

Q1 FY27

Promoter62.28%

FII4.87%

DII0.43%

Public32.41%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions